Clinical Trial Update: Effect of SRT2104 on Endotoxin-induced Inflammation [Phase 1]

View source ↗

Summary

Phase 1 trial by GlaxoSmithKline evaluating the sirtuin activator SRT2104 for endotoxin-induced inflammation in sepsis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• SRT2104 (SRT2104)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Sepsis | Phase 1 | Status: COMPLETED